Stockscreener 앱 받기
4.14
0.14%
-0.00
전일 마감가:
$4.14
열려 있는:
$4.12
하루 거래량:
772.17K
Relative Volume:
1.55
시가총액:
$1.29B
수익:
$391.87M
순이익/손실:
$-441.45M
주가수익비율:
-2.2378
EPS:
-1.85
순현금흐름:
$-301.21M
1주 성능:
-10.90%
1개월 성능:
-21.40%
6개월 성능:
-51.08%
1년 성능:
-66.33%
1일 변동 폭
$3.93
$4.20
1주일 범위
$3.93
$4.69
52주 변동 폭
$3.93
$12.25
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
4.14 | 1.29B | 391.87M | -441.45M | -301.21M | -1.85 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.78 | 58.95B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.42 | 54.36B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.09 | 50.19B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.80 | 39.85B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
474.10 | 20.38B | 3.13B | 1.27B | 1.12B | 26.39 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-11-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-14 | 개시 | UBS | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech begins European rollout of first-ever Simponi biosimilar Gobivaz - MSN
Alvotech (NASDAQ:ALVO) Cut to Strong Sell at Zacks Research - Defense World
Alvotech (NASDAQ:ALVO) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Alvotech (NASDAQ:ALVO) Faces Valuation Reset As Nasdaq Futures Turn - Kalkine Media
Alvotech stock hits 52-week low at $4.31 amid challenging year - Investing.com Canada
Alvotech (NASDAQ:ALVO) Reaches New 1-Year LowHere's Why - MarketBeat
Alvotech (NASDAQ:ALVO) Trading Down 5.7%Here's Why - MarketBeat
Alvotech (ALVO): A 378% Upside Potential In The Biosimilar Market - DirectorsTalk Interviews
Is There Now an Opportunity in Alvotech (ALVO) After a 64% One-Year Share Price Slide? - simplywall.st
Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump - Yahoo Finance
Alvotech AVT80 Progress And Sandoz Deals Shape Biosimilar Outlook - Yahoo Finance
How Alvotech Equity Warrant stock performs during Fed tightening cyclesEarnings Overview Summary & Free Safe Capital Growth Stock Tips - mfd.ru
Can Alvotech Equity Warrant maintain its current growth rateQuarterly Trade Summary & Accurate Entry and Exit Point Alerts - mfd.ru
Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80 - Finviz
Can Alvotech be recession proofJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - mfd.ru
12 Best Penny Stocks That Will Skyrocket - Insider Monkey
Is Alvotech the Next Big Biotech Rocket or Just Hype? Real Talk on This Viral Underdog Stock - AD HOC NEWS
Alvotech’s AVT03 Biosimilar Gains European Approval - MSN
How Alvotech (ALVO) Affects Rotational Strategy Timing - Stock Traders Daily
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar - MSN
Assessing Alvotech (ALVO) Valuation After AVT80 Trial Success And New Sandoz Agreements - simplywall.st
Alvotech Increases Share Capital by $125,000 Through Issuance of 12.5 Million Ordinary Shares - Quiver Quantitative
Alvotech Announces Increase in Number of Own Shares - ChartMill
Alvotech (ALVO) Investor Outlook: Exploring a 331% Potential Upside in the Biosimilars Market - DirectorsTalk Interviews
ALVO Investor News: If You Have Suffered Losses in Alvotech - GlobeNewswire
ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech - GlobeNewswire
Press releases provided by CNW - Techaeris
Aug Drivers: What is the Moat Score of Alvotech Equity WarrantQuarterly Trade Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Alvotech Faces Securities Claims Investigation - Intellectia AI
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - morningstar.com
Alvotech Enters Supply and Commercialization Agreements for Canada and Australia & New Zealand Covering Multiple Biosimilar Candidates - 富途牛牛
Are Expanded Sandoz Biosimilar Deals Quietly Reframing Alvotech’s Partnership Strategy and Scale Ambitions (ALVO)? - simplywall.st
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio - MSN
Positive PK Results Put Alvotech’s Vedolizumab Biosimilar On Path Toward Filings - Citeline News & Insights
Private Equity Firms Are Alvotech's (NASDAQ:ALVO) Biggest Owners and Were Hit After Market Cap Dropped US$63m - 富途牛牛
Alvotech Hits Pivotal Milestone With Positive PK Data for Entyvio Biosimilar AVT80 - TipRanks
Alvotech (NASDAQ: ALVO) posts positive pivotal data for Entyvio biosimilar - Stock Titan
Alvotech Reports Positive Top-line Pharmacokinetic Study Results For AVT80, A Biosimilar To Entyvio - Nasdaq
Why Is ALVO Stock Rising Pre-Market Today? - Stocktwits
Alvotech (NASDAQ:ALVO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Alvotech Reports Positive Results for AVT80 Clinical Study - Intellectia AI
Fuji Pharma Lifts Sales Outlook but Slashes Profit Forecast on Alvotech Valuation Loss - TipRanks
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® - The Manila Times
Alvotech Announces Positive Top-Line Results for AVT80 Biosimilar Study Compared to Entyvio® - Quiver Quantitative
Alvotech biosimilar to $6.4B Entyvio hits marks in pivotal study - Stock Titan
Alvotech (ALVO): A Bull Case Theory - Finviz
ROSEN, A LEADING NATIONAL FIRM, Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - marketscreener.com
Alvotech (ALVO): A bull case theory - MSN
Alvotech (ALVO) Growth Potential: A Deep Dive into Its 316.67% Upside and Biosimilar Innovations - DirectorsTalk Interviews
Is It Time To Reconsider Alvotech (ALVO) After Its Sharp Three-Year Share Price Slide? - simplywall.st
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - TMX Newsfile
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.45%
자본화:
|
볼륨(24시간):